Over the past year, there has been a lot of coverage on Seeking Alpha about Exact Sciences (EXAS) and Guardant Health (GH), two companies playing in the emerging precision oncology space. This article focuses on comparing the two companies which are both chasing the same market for non-invasive cancer diagnostics albeit from different entry points. For detailed coverage of each company individually, please see some recent articles from Seeking Alpha:
- Guardant Health: Undervalued Despite Rising Revenue And Margins
- Guardant Health: Growing But Possibly Overvalued?
- Guardant Health Looks Forward To